Top

Archives of Osteoporosis

Published in:

01-12-2023 | Antidepressant Drugs | Original Article

Bone mineral density response to antiosteoporotic drugs in older depressed adults

Authors: Eyyup Murat Efendioglu, Ahmet Cigiloglu, Ercument Ozturk, Zeynel Abidin Ozturk

Published in: Archives of Osteoporosis | Issue 1/2023

Abstract

Summary

Until now, studies did not evaluate the efficacy of antiosteoporotic agents in depressed patients. We demonstrate that the presence of depression and/or serotonergic antidepressant use was associated with non-response to osteoporosis treatment in older adults.

Purpose

This study aimed to evaluate the effects of depression and antidepressants on bone mineral density (BMD) and response to antiosteoporotic agents in older adults.

Methods

A total of 198 participants with osteoporosis, aged 65 and over, were included in this retrospective study. BMD was measured by dual-energy x-ray absorptiometry scanning at baseline and month 24.

Results

Eighty-three of the 198 patients had a diagnosis of depression, and all were serotonergic antidepressant users. Baseline BMD was similar in depressed and non-depressed patients. Lumbar spine BMD change was significantly lower in depressed patients than non-depressed patients (2.89% and 4.85%, respectively, p < 0.001). In addition, of those receiving denosumab treatment, depressed ones had lower lumbar spine BMD changes. Depression and/or antidepressant use was an independent variable for non-response to osteoporosis treatment in both the femoral neck (p = 0.008, OR = 2.61) and lumbar spine (p = 0.015, OR = 6.87), while alendronate and zoledronic acid were independent variables for non-response in the femoral neck and total femur compared to denosumab.

Conclusions

Our study has shown that the presence of depression and/or serotonergic antidepressant use was associated with non-response to osteoporosis treatment in older adults. The results of our study may guide physicians to make treatment decisions in older individuals with depression.

Rodda J, Walker Z, Carter J (2011) Depression in older adults. BMJ 343:d5219. https://doi.org/10.1136/bmj.d5219CrossRefPubMed

Schneider LS, Nelson JC, Clary CM et al (2003) An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 160:1277–1285. https://doi.org/10.1176/appi.ajp.160.7.1277CrossRefPubMed

Hayes D (2004) Recent developments in antidepressant therapy in special populations. Am J Manag Care 10:S179–S185PubMed

Wu Q, Liu B, Tonmoy S (2018) Depression and risk of fracture and bone loss: an updated meta-analysis of prospective studies. Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 29:1303–1312. https://doi.org/10.1007/s00198-018-4420-1CrossRef

Sözen T, Özışık L, Başaran NÇ (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46–56. https://doi.org/10.5152/eurjrheum.2016.048CrossRefPubMed

Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374:254–262. https://doi.org/10.1056/NEJMcp1513724CrossRefPubMed

Schweiger JU, Schweiger U, Hüppe M et al (2016) Bone density and depressive disorder: a meta-analysis. Brain Behav 6:e00489. https://doi.org/10.1002/brb3.489CrossRefPubMedPubMedCentral

Yirmiya R, Bab I (2009) Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry 66:423–432. https://doi.org/10.1016/j.biopsych.2009.03.016CrossRefPubMed

Cizza G, Primma S, Csako G (2009) Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 20:367–373. https://doi.org/10.1016/j.tem.2009.05.003CrossRefPubMedPubMedCentral

10.

Rizzoli R, Cooper C, Reginster J-Y et al (2012) Antidepressant medications and osteoporosis. Bone 51:606–613. https://doi.org/10.1016/j.bone.2012.05.018CrossRefPubMed

11.

Tsapakis EM, Gamie Z, Tran GT et al (2012) The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 27:156–169. https://doi.org/10.1016/j.eurpsy.2010.10.006CrossRefPubMed

12.

Gustafsson BI, Thommesen L, Stunes AK et al (2006) Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139–151. https://doi.org/10.1002/jcb.20734CrossRefPubMed

13.

Westbroek I, van der Plas A, de Rooij KE et al (2001) Expression of serotonin receptors in bone. J Biol Chem 276:28961–28968. https://doi.org/10.1074/jbc.M101824200CrossRefPubMed

14.

Diem SJ, Blackwell TL, Stone KL et al (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167:1240–1245. https://doi.org/10.1001/archinte.167.12.1240CrossRefPubMed

15.

Williams LJ, Henry MJ, Berk M et al (2008) Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 23:84–87. https://doi.org/10.1097/YIC.0b013e3282f2b3bbCrossRefPubMed

16.

Feuer AJ, Demmer RT, Thai A, Vogiatzi MG (2015) Use of selective serotonin reuptake inhibitors and bone mass in adolescents: an NHANES study. Bone 78:28–33. https://doi.org/10.1016/j.bone.2015.04.042CrossRefPubMed

17.

Bruyère O, Reginster J-Y (2015) Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine 48:65–68. https://doi.org/10.1007/s12020-014-0357-0CrossRefPubMed

18.

Chau K, Atkinson SA, Taylor VH (2012) Are selective serotonin reuptake inhibitors a secondary cause of low bone density? J Osteoporos 2012:323061. https://doi.org/10.1155/2012/323061CrossRefPubMedPubMedCentral

19.

Fernandes BS, Hodge JM, Pasco JA et al (2016) Effects of depression and serotonergic antidepressants on bone: mechanisms and ımplications for the treatment of depression. Drugs Aging 33:21–25. https://doi.org/10.1007/s40266-015-0323-4CrossRefPubMed

20.

Haney EM, Warden SJ, Bliziotes MM (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13–17. https://doi.org/10.1016/j.bone.2009.07.083CrossRefPubMed

21.

Rosen HN, Drezner MK, Rosen CJ, Schmader KE, Mulder JE (2017) Overview of the management of osteoporosis in postmenopausal women. Available at: www.uptodate.com. Accessed 4 Feb 2022

22.

Mezuk B, Eaton WW, Golden SH (2008) Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 19:1–12. https://doi.org/10.1007/s00198-007-0449-2CrossRef

23.

Haney EM, Warden SJ (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 8:133–145PubMed

24.

Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457. https://doi.org/10.1016/j.biopsych.2009.09.033CrossRefPubMed

25.

Maier A, Riedel-Heller SG, Pabst A, Luppa M (2021) Risk factors and protective factors of depression in older people 65+ A systematic review. PLoS One 16:e0251326. https://doi.org/10.1371/journal.pone.0251326CrossRefPubMedPubMedCentral

26.

Yang Y-T, Wang Y-H, Chiu H-T et al (2015) Functional limitations and somatic diseases are independent predictors for incident depressive disorders in seniors: findings from a nationwide longitudinal study. Arch Gerontol Geriatr 61:371–377. https://doi.org/10.1016/j.archger.2015.07.005CrossRefPubMed

27.

Cummings SR, Cawthon PM, Ensrud KE et al (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res Off J Am Soc Bone Miner Res 21:1550–1556. https://doi.org/10.1359/jbmr.060708CrossRef

28.

Zhang H, Li K, Zhao Y et al (2020) Long-term use of fluoxetine accelerates bone loss through the disruption of sphingolipids metabolism in bone marrow adipose tissue. Transl Psychiatry 10:138. https://doi.org/10.1038/s41398-020-0819-5CrossRefPubMedPubMedCentral

29.

Hochberg MC, Thompson DE, Black DM et al (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res Off J Am Soc Bone Miner Res 20:971–976. https://doi.org/10.1359/JBMR.050104CrossRef

30.

Boonen S, Black DM, Colón-Emeric CS et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292–299. https://doi.org/10.1111/j.1532-5415.2009.02673.xCrossRefPubMedPubMedCentral

31.

McClung MR, Boonen S, Törring O et al (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 27:211–218. https://doi.org/10.1002/jbmr.536CrossRef

Title: Bone mineral density response to antiosteoporotic drugs in older depressed adults
Authors: Eyyup Murat Efendioglu
Ahmet Cigiloglu
Ercument Ozturk
Zeynel Abidin Ozturk
Publication date: 01-12-2023
Publisher: Springer London
Keywords: Antidepressant Drugs
Affective Disorder
Affective Disorder
Osteoporosis
Osteoporosis
Denosumab
Antidepressant Drugs
Denosumab
Zoledronic Acid
Published in: Archives of Osteoporosis / Issue 1/2023
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-023-01219-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bone mineral density response to antiosteoporotic drugs in older depressed adults

Abstract

Summary

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Association of early-life famine exposure with low bone mass in adulthood

External validation of FRISBEE 5-year fracture prediction models: a registry-based cohort study

Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia

Role of lifestyle factors in mediating the effect of educational attainment on bone mineral density: a Mendelian randomization study

Two-country comparison of the prescription of bone protection medication before and early after hip fracture

Spinal pseudoarthrosis following osteoporotic vertebral fracture: prevalence, risk factors, and influence on patients’ activities of daily living 1 year after injury